Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Joint Authors
Gomez-Mancilla, Baltazar
Di Paolo, Thérèse
Gasparini, Fabrizio
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-06-18
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson’s disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA.
There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskinesia (LID).
Although initial preclinical studies with ionotropic glutamate receptor antagonists showed antiparkinsonian and antidyskinetic activity, their clinical use was limited due to psychiatric adverse effects, with the exception of amantadine, a weak N-methyl-d-aspartate (NMDA) antagonist, currently used to reduce dyskinesia in PD patients.
Metabotropic receptor (mGlu receptor) modulators were considered to have a more favourable side-effect profile, and several agents have been studied in preclinical models of PD.
The most promising results have been seen clinically with selective antagonists of mGlu5 receptor and preclinically with selective positive allosteric modulators of mGlu4 receptor.
The growing understanding of glutamate receptor crosstalk also raises the possibility of more precise modulation of glutamatergic transmission, which may lead to the development of more effective agents for PD.
American Psychological Association (APA)
Gasparini, Fabrizio& Di Paolo, Thérèse& Gomez-Mancilla, Baltazar. 2013. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy. Parkinson’s Disease،Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1011421
Modern Language Association (MLA)
Gasparini, Fabrizio…[et al.]. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy. Parkinson’s Disease No. 2013 (2013), pp.1-11.
https://search.emarefa.net/detail/BIM-1011421
American Medical Association (AMA)
Gasparini, Fabrizio& Di Paolo, Thérèse& Gomez-Mancilla, Baltazar. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy. Parkinson’s Disease. 2013. Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1011421
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1011421